BR112022018682A2 - Anticorpos anti-ceramida - Google Patents

Anticorpos anti-ceramida

Info

Publication number
BR112022018682A2
BR112022018682A2 BR112022018682A BR112022018682A BR112022018682A2 BR 112022018682 A2 BR112022018682 A2 BR 112022018682A2 BR 112022018682 A BR112022018682 A BR 112022018682A BR 112022018682 A BR112022018682 A BR 112022018682A BR 112022018682 A2 BR112022018682 A2 BR 112022018682A2
Authority
BR
Brazil
Prior art keywords
antibodies
individual
ceramid
antigen
need
Prior art date
Application number
BR112022018682A
Other languages
English (en)
Portuguese (pt)
Inventor
Kolesnick Richard
Tinkelenberg Arthur
Kuo-Ming Wang Jordon
Wu Yinan
Wang Yong
Levy Raphael
Original Assignee
Memorial Sloan Kettering Cancer Center
Ceram Holding Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center, Ceram Holding Llc filed Critical Memorial Sloan Kettering Cancer Center
Publication of BR112022018682A2 publication Critical patent/BR112022018682A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112022018682A 2020-03-18 2021-03-18 Anticorpos anti-ceramida BR112022018682A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062991232P 2020-03-18 2020-03-18
PCT/US2021/022914 WO2021188770A1 (en) 2020-03-18 2021-03-18 Anti-ceramide antibodies

Publications (1)

Publication Number Publication Date
BR112022018682A2 true BR112022018682A2 (pt) 2023-02-14

Family

ID=77771401

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022018682A BR112022018682A2 (pt) 2020-03-18 2021-03-18 Anticorpos anti-ceramida

Country Status (11)

Country Link
US (1) US20230167197A1 (enExample)
EP (1) EP4121110A4 (enExample)
JP (1) JP7809067B2 (enExample)
KR (1) KR20230031814A (enExample)
CN (1) CN115811987A (enExample)
AU (1) AU2021236669A1 (enExample)
BR (1) BR112022018682A2 (enExample)
CA (1) CA3172201A1 (enExample)
IL (1) IL296550A (enExample)
MX (1) MX2022011591A (enExample)
WO (1) WO2021188770A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016022883A1 (en) 2014-08-07 2016-02-11 Memorial Sloan-Kettering Cancer Center Anti-ceramide antibodies
EP4308231A4 (en) * 2021-03-16 2025-01-29 Memorial Sloan Kettering Cancer Center IMPROVING WOUND HEALING WITH ANTI-CERAMIDE ANTIBODIES

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4579821A (en) 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
DE69233013T2 (de) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP1024198A3 (en) 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
AU687117B2 (en) 1993-10-25 1998-02-19 Canji, Inc. Recombinant adenoviral vector and methods of use
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
US7078387B1 (en) 1998-12-28 2006-07-18 Arch Development Corp. Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
EP2289550A3 (en) 2000-01-27 2012-02-15 MedImmune, LLC Ultra high affinity neutralizing antibodies
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
AU2005325801A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
EA201170357A1 (ru) * 2008-08-20 2012-05-30 Сентокор Орто Байотек Инк. Инженерные антитела к il-13: композиции, способы и применение
CA2785907A1 (en) 2009-12-29 2011-07-28 Emergent Product Development Seattle, Llc Ron binding constructs and methods of use thereof
US20130129723A1 (en) 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof
US9833949B2 (en) 2011-08-29 2017-12-05 Impossible Objects, Inc. Apparatus for fabricating three-dimensional printed composites
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
WO2016022883A1 (en) 2014-08-07 2016-02-11 Memorial Sloan-Kettering Cancer Center Anti-ceramide antibodies
TWI632160B (zh) * 2015-01-16 2018-08-11 中央研究院 具有標的部分及效應部分的分子構建體
CN118948892A (zh) * 2017-05-01 2024-11-15 朱诺治疗学股份有限公司 细胞疗法与免疫调节化合物的组合
WO2019237035A1 (en) * 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
US10975169B1 (en) * 2019-09-27 2021-04-13 Memorial Sloan Kettering Cancer Center Methods for treating diabetic retinopathy using anti-ceramide monoclonal antibody 2A2

Also Published As

Publication number Publication date
CA3172201A1 (en) 2021-09-23
CN115811987A (zh) 2023-03-17
EP4121110A1 (en) 2023-01-25
KR20230031814A (ko) 2023-03-07
MX2022011591A (es) 2023-03-06
AU2021236669A1 (en) 2022-11-10
WO2021188770A1 (en) 2021-09-23
JP2023534779A (ja) 2023-08-14
IL296550A (en) 2022-11-01
JP7809067B2 (ja) 2026-01-30
EP4121110A4 (en) 2024-06-12
US20230167197A1 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
Cardoso et al. Short‐and long‐term mortality after bariatric surgery: a systematic review and meta‐analysis
CL2019003728A1 (es) Moléculas de unión a antígeno que comprenden un trímero de ligando de la familia de tnf. (divisional solicitud 201701000)
Sutton et al. Anti-Inflammatory mechanisms of enteric Heligmosomoides polygyrus infection against trinitrobenzene sulfonic acid-induced colitis in a murine model
BRPI0812913A8 (pt) Anticorpos monoclonais ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotideo, método para produzir os referidos anticorpos ou fragmentos de anticorpos, composição que os compreende e uso dos mesmos
Herrero et al. Macrophage migration inhibitory factor receptor CD74 mediates alphavirus‐induced arthritis and myositis in murine models of alphavirus infection
BR112016011401A2 (pt) moduladores de aplnr e utilizações dos mesmos
BR112022003335A2 (pt) Conjugados de il-2 e métodos de uso para tratar doenças autoimunes
BR112019007714A2 (pt) anticorpos de 4-1bb anti-humanos e usos dos mesmos
Cox et al. Cadmium attenuates the macrophage response to LPS through inhibition of the NF-κB pathway
BR112022000328A2 (pt) Inibidores peptídicos do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias
MX387530B (es) Anticuerpo anti-receptor cgrp para usarse en tratar o prevenir dolor de cabeza por migraña.
BR112022018682A2 (pt) Anticorpos anti-ceramida
BR112018072681A2 (pt) anticorpos anti-il-1r3 humanizados
MX2024009860A (es) Anticuerpos monoclonales humanos que se dirigen ampliamente a los coronavirus
BR112022023989A2 (pt) Anticorpos anti-pd-1
Lee et al. SARS-CoV-2 spike protein promotes inflammatory cytokine activation and aggravates rheumatoid arthritis
MX2022003668A (es) Metodos y composiciones para el tratamiento de la retinopatia diabetica.
BR112021016791A2 (pt) Proteínas de ligação de antígenos que se ligam a bcma
Miletić et al. Serum interleukin-17 & nitric oxide levels in patients with primary Sjögren's syndrome
Barbier et al. Endogenous interleukin-33 acts as an alarmin in liver ischemia-reperfusion and is associated with injury after human liver transplantation
MX2021010283A (es) Composiciones de anticuerpo anti-cd6 y metodos para tratar lupus.
BR112022004302A2 (pt) Anticorpos anti-il-27 e usos dos mesmos
Günendi et al. The impact of COVID-19 on familial Mediterranean fever: a nationwide study
BR112023005684A2 (pt) Anticorpos contra sars-cov-2
Cassisa et al. Cutaneous vasculitis: insights into pathogenesis and histopathological features